Guy Berchem

The paper identifies impaired monocyte states and trajectories in glioblastoma patients through immune profiling, revealing systemic immune reprogramming and potential therapeutic targets.

ACB1801 enhances anti-PD-1 therapy efficacy in MSS CRC by reprogramming the TME through metabolic reprogramming and STAT1 signaling activation.

This study integrates multi-omics and functional drug screening in patient-derived organoids to identify personalized therapeutic vulnerabilities in adult high-grade gliomas, finding distinct drug responses in IDH1 mutant and MYCN-amplified tumors.

This study shows that targeting ACKR2 enhances anti-PD-1 immunotherapy efficacy in melanoma by improving the tumor microenvironment and immune cell infiltration.